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Abstract
Background: To investigate the utilization of health care services before and after transfer from pediatric to adult
rheumatology care in clinical practice.
Methods: Using US commercial claims data from January 2005 through August 2012, we identified individuals
with a JIA diagnosis code from a pediatric rheumatologist followed by any diagnosis code from an adult
rheumatologist. Individuals had 6 months observable time before the last pediatric visit and 6 months after the
first adult visit. Medication, emergency room, physical therapy use, and diagnosis codes were compared between the
pediatric and adult interval using McNemar’s test. The proportion of days covered (PDC) of TNFi for the time between
last pediatric and first adult visit was calculated.
Results: We identified 58 individuals with JIA who transferred from pediatric to adult rheumatology care after the age
of 14. The median age at the last pediatric rheumatology visit was 18.1 years old and the median transfer interval was
195 days. 29 % of patients received NSAIDs in the adult interval compared to 43 % in the pediatric interval (p = 0.06). In
the pediatric interval, 71 % received a JRA and 0 % received an RA physician diagnosis code compared to 28 and 45 %,
respectively, in the adult interval. The median PDC for patients receiving a TNFi was 0.75 during the transfer interval.
Conclusion: Individuals with JIA who transferred to adult care were more likely receive a diagnosis of RA instead of
JRA and were less likely to receive NSAIDs, but had no significant immediate changes to other medication use.
Keywords: Juvenile idiopathic arthritis (JIA), Transition to adult care, Administrative claims
Abbreviations: ER, Emergency room; ICD-9, International classification of diseases, 9th edition; ILAR, International
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Background
Juvenile idiopathic arthritis (JIA) is a chronic disease
that begins in childhood with up to 50 % of patients
continuing to have active arthritis in adulthood [1–4].
JIA is an umbrella term for a heterogenous group of in-
flammatory arthritides; most children with JIA do not
have a disease similar to rheumatoid arthritis. Accordingly,
children with JIA not only have complications related to
the age of onset of disease, such as growth limitations or
psychosocial issues [5–7], but also have disease manifesta-
tions that are not commonly seen in rheumatoid arthritis
(RA) such as silent anterior uveitis [8]. Chronic disease in
childhood can affect linear growth as well as psychosocial
development due to additional stress, medical experiences,
and alterations in normal social and emotional develop-
ment [7]. There is an emphasis on growth and develop-
ment in pediatric and pediatric rheumatology training that
represents an important difference between pediatric and
adult rheumatologists.
As with all chronic diseases that begin in childhood,
patients who are seen by a pediatric specialist in child-
hood must transition to an adult specialist at the age of
adulthood, usually near the end of adolescence. Transi-
tion is a complicated process that requires coordination
of care in a chronologic and developmentally appropri-
ate setting in order to increase the likelihood of success
[9]. Ideally the process of transition begins in early ado-
lescence to educate and prepare individuals for the adult
experiences of disease and healthcare and culminates in
the transfer from a pediatric specialist to adult specialist
[10]. Since the time of transition, both the age of adoles-
cence and transfer of care, can be a high risk period for
disease flares or complications, improving the transition
process for young adults with special health care needs,
including those with a rheumatologic diagnosis, has be-
come a focus of multiple organizations [11]. The clinical
pattern of individuals with JIA transitioning and trans-
ferring from pediatric rheumatologists to adult rheuma-
tologists is largely unknown in the United States.
To understand the barriers that exist for patients tran-
sitioning from pediatric rheumatology to adult rheuma-
tology, we must first know what is happening currently
in clinical practice. Transition programs vary greatly across
U.S. pediatric rheumatology clinics and most report that
they have an informal process [12]. The goal of this study
was to evaluate the health utilization patterns during the
peri-transfer stage of transition. We hypothesized that indi-
viduals with JIA would receive alternate diagnoses from
pediatric and adult providers (e.g. RA instead of juvenile
rheumatoid arthritis (JRA)), they would have a change in
medication use, more patients would receive physical ther-
apy in the adult interval, more patients would visit an emer-
gency room in the transfer and adult intervals, and that
patients would have poor compliance with medications
during the transfer period. Using national administrative
claims from a large commercial US health insurer, we in-
vestigated the utilization of health care services before
and after transfer.
Methods
We performed this study using a national commercial
insurance administrative claims database from January
2005 through September 2012. This claims database has
been used previously to describe the trends in medication
use among patients with JIA [13]. Individual providers are
given unique identifiers within this database that are linked
to their individual National Provider Identifier (NPI) as
well as any group NPI number that the claims may be
billed under. We utilized this unique identifier to identify
pediatric rheumatologists and adult rheumatologists based
upon their individual NPI taxonomy code. NPI taxonomy
codes are assigned by the individual or institution that
manages the individual NPI account [14]. Pediatric rheu-
matologists were identified by taxonomy code 2080P0216X
(pediatric rheumatology) or 20800000X with 207RR0500X
(pediatrics and rheumatology). Adult rheumatologists
were identified by taxonomy code 207RR0500X without
20800000X. The providers who met the taxonomy criteria
for pediatric rheumatologist were reviewed by MLM
with >90 % of individuals identified by name as practicing
pediatric rheumatologists by training or board certification.
To identify the study population, we first identified
individuals in the database with ≥ 2 International Classi-
fication of Diseases, 9th edition (ICD-9) codes associated
with a physician encounter between 7 days and 6 months
apart and consistent with JIA (714.3x (JRA), 696.0 (Psoriatic
Arthritis), 720.xx (Spondyloarthritis)) or 1 diagnosis code
consistent with JIA and 1 prescription for methotrexate
(MTX) or a tumor necrosis factor inhibitor (TNFi). This
claims definition of JIA has been used in other pharma-
coepidemiologic studies [15–17]. Individuals were also
required to have a JIA diagnosis code from a physician
with a pediatric rheumatology NPI taxonomy code followed
by a diagnosis code from a physician with a different NPI
number associated with an adult rheumatology taxonomy
code and without a subsequent pediatric rheumatology
claim. We required individuals to have at least 6 months of
continuous coverage before the last pediatric rheuma-
tology visit (pediatric interval) and after the first adult
rheumatology visit (adult interval). There was no limit
on the length of the time between the pediatric and
adult rheumatology visits (transfer interval). The first
adult rheumatology visit was defined as the transfer
point; this resulted in 3 distinct intervals, pediatric,
transfer, and adult (Fig. 1). We excluded individuals
who were <14 years of age at the transfer point to in-
crease the likelihood that the transfer was due to age
and not geographic relocation.
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We collected demographic information including age
at last pediatric visit and at transfer point, gender, US
census region, calendar year of transfer point, length of
transfer interval (in days), and physician diagnosis ICD-9
codes related to JIA (JRA, psoriatic arthritis, spondyloar-
thritis, rheumatoid arthritis) in both the pediatric and
adult intervals. We determined the use of methotrexate
(MTX), tumor necrosis factor inhibitors (TNFi), oral glu-
cocorticoids, opiates, and non-steroidal anti-inflammatory
drugs (NSAIDs) using pharmacy and infusion claims for
each interval. Other biologics had infrequent use in this
population and were not included [13]. We also identified
individuals who utilized an emergency room (ER) by phys-
ician evaluation and management codes and physical ther-
apy (PT) or occupational therapy by current procedural
terminology codes. Medication, ER use, PT use, and diag-
nosis codes were compared between the pediatric and
adult interval using McNemar’s test. The proportion of
days covered (PDC) of TNFi for the transfer interval was
calculated for all patients who received a TNFi during the
pediatric interval. All p values were two sided and consid-
ered significant at values ≤ 0.05. Data analyses were per-
formed using SAS software, Version 9.3 (copyright, SAS
Institute Inc, Cary, NC, USA). The university institutional
review board approved the study protocol. Although JIA
is the accepted inclusive terminology for this group of
diseases, JRA persists within the ICD-9 definition.
Henceforth, JRA will only be used in reference to the
ICD-9 code 714.3.
Results
We identified 58 individuals with JIA who transferred
from pediatric to adult rheumatology care and were at
least 14 years old. A total of 2,988 individuals met the
diagnosis of JIA in the available claims data; most were
excluded because they did not have evidence of transfer
to an adult rheumatologist. The median age at the last
pediatric rheumatology visit was 18.1 years old (interquar-
tile range (IQR) 17–19.6 years) and the median age at the
first adult rheumatology visit was 18.9 years old (IQR 18–
20 years). The median length of the transfer interval (time
from last pediatric rheumatology visit to first adult rheuma-
tology visit) was 195 days (IQR 89–371 days) (Fig. 2). All
US census regions and years 2006–2012 were represented;
79 % of the individuals were female (Table 1).
During the 6 month pediatric interval, 33 % of patients
received a TNFi, 24 % MTX (either oral or subcutaneous),
28 % oral glucocorticoids, 28 % opiates, and 43 % NSAIDs.
These numbers did not significantly change compared to
the 6 month adult interval where 41 % of patients received
a TNFi, 21 % MTX (either oral or subcutaneous), 28 %
glucocorticoids, 29 % opiates, and 29 % NSAIDs. These
patients also continued to receive medications during the
transfer interval with 24 % receiving a TNFi, 21 % MTX
(either oral or subcutaneous), 31 % glucocorticoids, 21 %
opiates, and 36 % NSAIDs (Table 2).
There was no significant difference in the number of
patients receiving physical therapy or visiting an Emer-
gency Room between the pediatric and adult intervals.
The proportions of JRA and RA ICD-9 codes were sig-
nificantly different between the pediatric and the adult
intervals. No patient received an RA diagnosis during
the pediatric rheumatology interval. Fewer patients re-
ceived a JRA diagnosis (28 %) and more received an RA
diagnosis (45 %) during the adult interval. There was no
significant change in the number of patients who received
a diagnosis for psoriatic arthritis or spondyloarthropathy
between the intervals (Table 2). Of the 19 patients receiv-
ing a TNFi during the pediatric interval, the median PDC
for TNFi was 0.75 (SD 0.332) during the transfer interval.
Discussion
We were able to identify individuals with JIA who trans-
ferred from pediatric to adult rheumatology care in a
national commercial health insurance population. While
most patients transferred at the end of adolescence and
had a median 6 month transfer interval, approximately
25 % of the children had a gap greater than 1 year be-
tween their last pediatric rheumatology visit and their
first adult rheumatology visit. A clinic-based study from
Canada reported that half of the individuals with JIA did
not follow up with an adult rheumatologist within 2 years
Fig. 1 Graphical depiction of pediatric, transfer, and adult intervals
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of their last pediatric visit [18]. A clinic based chart review
of all transferred patients over 5 years from a clinic in the
United Kingdom with an established transition program
reported a mean age at transition of 17 years old with a
median of 115 days between pediatric and adult visits [19].
The patients that we have identified are likely to have
more severe disease given the high proportion of patients
receiving and continuing a rheumatologic medication and
may have motivated these patients to pursue rheumatol-
ogy care in adulthood.
After transfer to adult care, there was very little change in
the medications received by individuals with JIA. There was
a non-significant trend for more patients to be on a TNFi
and fewer to be prescribed NSAIDs between the pediatric
and adult interval. Glucocorticoids and opiates are received
in a large proportion of this population. While we do not
have clinical information to know the reasons for prescrip-
tion, we have published similar rates for glucocorticoid use
previously [13]. In addition, there was little change from
the pediatric to the transfer interval. Medication adherence
can only be calculated using evidence and timing of refills
in administrative claims data as it lacks any clinical infor-
mation regarding patient reported adherence. In this data
set, individuals who received a TNFi in the pediatric inter-
val had a PDC of 0.75 for TNFi use during the transfer
interval. A PDC of 80 % in claims data is typically inter-
preted as good adherence; our PDC of 75 % indicates fair
adherence during the transfer interval [20].
Individuals with JIA who transferred to adult care were
more likely receive a diagnosis of RA instead of JRA, but
patients with psoriatic arthritis or spondyloarthropathy
maintained the same diagnosis codes. JIA is classified ac-
cording to the International League Against Rheumatism
(ILAR) criteria [21], but ICD-9 diagnosis codes reflect
an earlier classification system. Individuals with JIA con-
tinue to have JIA in adulthood; however in this US com-
mercial claims database that is not the clinical pattern. It
is unknown if the billing code reclassification is due to
the limitations of ICD-9 diagnosis codes, ease of using
an RA code based on available billing forms or for medi-
cation approval, or simple misclassification. This finding
highlights the challenges of using claims data for longi-
tudinal or adult outcome studies of patients with JIA
Fig. 2 Histogram of transfer interval length in days







Age (median (IQR)) 18.1 (17–19.6) 18.9 (18–20)
Female 46 (79.31 %)
Time, days (median (IQR) 195 (89–371)
Census Region
Northeast 22 (37.9 %)
South 16 (27.6 %)
Mid West 8 (13.8 %)
West 12 (20.7 %)
Calendar Year
2005 0
2006 8 (13.79 %)
2007 12 (20.69 %)
2008 9 (15.52 %)
2009 8 (13.79 %)
2010 5 (8.62 %)
2011 13 (22.41 %)
2012 3 (5.17 %)
Individuals with JIA who transfer at >14 years old, n = 58. Age at last pediatric
visit and first adult visit, median (IQR). Length of transfer interval in days,
median (IQR); pediatric and adult intervals were 183 days by definition. U.S.
Census Region and Calendar Year at first adult rheumatology visit, n (%)
Mannion et al. Pediatric Rheumatology  (2016) 14:49 Page 4 of 6
that have been identified in other longitudinal studies
[22]. It is unclear how transition to the ICD-10 coding
system will affect this challenge to longitudinal follow
up; the increase in coding options is unlikely to affect
misclassification and billing habits of physicians. Most of
the individuals with JIA identified continued to receive
medications and did not have significant changes be-
tween intervals; patients who successfully transfer main-
tain disease treatment.
This study is limited by the small sample size. We did
not evaluate the patients that continue to see pediatric
rheumatologists into adulthood or only see adult rheu-
matologists from childhood as there were no differences
identified in the patients who did transfer. Due to our
inclusion requirements and the years for which we had
data, we were limited by right censoring and the inability
to discern the individuals with JIA who failed to follow
up and had an unsuccessful transfer versus the patients
who failed to follow up because they were in drug free
remission and perhaps did not need to transfer to adult
rheumatology care. The individuals who may have oli-
goarticular JIA and may not need adult rheumatology
care cannot be uniquely identified using claims data.
Those individuals who unsuccessfully transfer warrant
further evaluation to determine the barriers to transition
and what disease outcomes occur with unsuccessful
transition, however those additional studies will have to
be done via a different data source such as a longitudinal
cohort study. We are unable to identify failed transitions
in an administrative claims dataset due to right censoring;
this would be better studied in a prospective or clinical
dataset. We used data from commercial insurance that may
not be generalizable to individuals with non-commercial
insurance. In addition to the potential cost of health during
the transition period, there are missing costs associated
with the transition process and planning. The AAP recom-
mends the use of billing for time and counseling related to
transition [10]; however we are unable to assess these
additional costs without clinical documentation.
Conclusions
Understanding the current patterns of transition and
transfer for individuals with JIA will contribute to the
evaluation of barriers that limit patients from continuing
rheumatologic care. Future studies can help identify
additional risk factors or clinical features that contribute to
the success or failure of transition to improve the rates of
successful transition of individuals with JIA from pediatric
to adult rheumatology care. There are many programs
being developed to improve the process of transition and
transfer from pediatric to adult rheumatology care. In this
administrative claims database, the patients who were seen
by an adult rheumatologist did not have significant changes
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Table 2 Health Care Claims of Individuals with JIA during transfer
Pediatric Interval Transfer Interval Adult Interval p value
MTX PO 10 (17.24 %) 9 (15.52 %) 11 (18.97 %) 0.8
MTX SQ 4 (6.90 %) 3 (5.17 %) 1 (1.72 %) 0.1
TNFi 19 (32.76 %) 14 (24.14 %) 24 (41.38 %) 0.2
GC 16 (27.59 %) 18 (31.03 %) 16 (27.59 %) 1
OP 16 (27.59 %) 12 (20.69 %) 17 (29.31 %) 0.8
NSAID 25 (43.10 %) 21 (36.21 %) 17 (29.31 %) 0.06
ER 11 (18.97 %) 11 (18.97 %) 12 (20.69 %) 0.8
PT 14 (24.14 %) 10 (17.24 %) 11 (18.97 %) 0.4
Physician diagnosis codes
JRA (714.3x) 41 (70.69 %) 16 (27.59 %) <0.0001
Psoriatic arthritis (696.0) 3 (5.17 %) 3 (5.17 %) 1
Spondyloarthritis (720.xx) 16 (27.59 %) 14 (24.14 %) 0.3
RA (714.0) 0 (0 %) 26 (44.83 %)
Number of individuals who received medications, had ≥ PT visit, ≥ 1 ER visit, and physician diagnosis codes (not mutually exclusive) during each interval, n (%).
The pediatric interval and adult interval proportions were compared by McNemar’s test with resulting p value
Abbreviations: MTX methotrexate, PO oral, SQ subcutaneous, TNFi tumor necrosis factor inhibitor, GC glucocorticoids, OP opiates, ER Emergency Room, PT physical
therapy, JRA Juvenile Rheumatoid Arthritis, RA rheumatoid arthritis
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